11:58 AM
 | 
Apr 02, 2019
 |  BC Extra  |  Financial News

Fusion raises $105M series B for radiopharmaceutical pipeline

Aiming to advance its pipeline of targeted α-particle radiopharmaceuticals for cancer, Fusion raised $105 million in an oversubscribed series B round led by Varian and new investor OrbiMed Advisors.

Fusion Pharmaceuticals Inc. (Hamilton, Ontario) labels antibodies with the...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >